Abelmoschus manihot – a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial
作者: Ping LiYi-zhi ChenHong-li LinZhao-hui NiYong-li ZhanRong WangHong-tao YangJing-ai FangNian-song WangWen-ge LiXue-feng SunXiang-mei Chen
作者单位: 1State Key Laboratory of Kidney Disease, 2011DAV00088, Chinese PLA General Hospital
2The First Affiliated Hospital of Dalian Medical University
3Renji Hospital, Shanghai Jiao Tong University School of Medicine
4Guang’ anmen Hospital, China Academy of Chinese Medical Sciences
5Shandong Provincial Hospital
6First Teaching Hospital of Tianjin University of TCM
7The First Hospital of Shanxi Medical University
8The Sixth Affiliated Hospital of Shanghai Jiao Tong University School of Medicine
9China-Japan Friendship Hospital
10Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases
11Department of N
刊名: Trials, 2017, Vol.18 (1)
来源数据库: Springer Nature Journal
DOI: 10.1186/s13063-016-1774-6
关键词: IgA nephropathyTraditional Chinese medicineAbelmoschus manihotRandomized controlled study
英文摘要: IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, but effective therapy remains limited and many patients progress to end-stage renal disease (ESRD). Only angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blockers (ARB) show a high level of evidence (1B level) of being of value in the treatment for IgAN according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. However, traditional Chinese medicine has raised attention in kidney disease research. Abelmoschus manihot , a single medicament of traditional Chinese medicine has shown therapeutic effects in primary glomerular disease according to the randomized controlled clinical trial that we have completed. Here, we conduct a new study to assess the efficacy...
原始语种摘要: IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, but effective therapy remains limited and many patients progress to end-stage renal disease (ESRD). Only angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blockers (ARB) show a high level of evidence (1B level) of being of value in the treatment for IgAN according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. However, traditional Chinese medicine has raised attention in kidney disease research. Abelmoschus manihot , a single medicament of traditional Chinese medicine has shown therapeutic effects in primary glomerular disease according to the randomized controlled clinical trial that we have completed. Here, we conduct a new study to assess the efficacy...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:2.206 (2012)

×
关键词翻译
关键词翻译
  • manihot 木薯
  • nephropathy 肾病
  • controlled 受控
  • medicine 
  • traditional 传统
  • study 学习
  • Chinese 汉语
  • IgA 免疫球蛋白 A
  • angiotensin 血管紧张肽
  • treating 处理